THERAPEUTIC APPLICATION OF ISOLATED NATURALLY-OCCURRING SOLUBLE TRUNCATED FORMS OF IL-23 RECEPTOR
The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease.
This application is a division of U.S. application Ser. No. 13/065,878 filed Mar. 31, 2011, which claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application Nos. 61/341,465 and 61/341,457 filed Mar. 31, 2010, the contents of which are incorporated by reference herein in their entireties.
FIELD OF THE INVENTIONThe present invention relates to a therapeutic application of an isolated recombinant IL-23 receptor (IL-23Rα). This particular recombinant IL-23Rα is discovered as a soluble translated form (e.g., Δ9 or Δ8,9) as a result of the alternative splicing of the IL-23Rα gene. It exists as a naturally-occurring soluble truncated form of IL-23Rα. The soluble translated IL-23Rα has a unique eight (8) amino acid sequence (GLKEGSYC) at its C-terminus, due to the alternative translation reading frame on exon 10. The present invention provides a soluble truncated IL-23Rα that is useful as a therapeutic agent to inhibit cell signaling mediated by IL-23 necessary for differentiation of Th17 cells in immunological diseases including inflammatory bowel diseases (e.g., Crohn's disease), asthma, and other pathological diseases (e.g., graft vs. host disease).
BACKGROUND OF THE INVENTIONIL-23 is a heterodimeric molecule comprising a p19 subunit and a p40 subunit that are two disulfide-linked. IL-23 is speculated to play an essential role in chronic inflammation and autoimmune diseases in humans. Mice lacking p19 exhibit a decreased pro-inflammatory response to experimental autoimmune encephalomyelitis, inflammatory bowel disease and collagen-induced arthritis. While IL-23 per se cannot induce the differentiation of naïve CD4 T-cells into Th-17 cells in vitro, the differentiation of Th17 cells in vivo may require IL-23. The observed protective effect in p19-deficient mice may relate to the lack of differentiation of Th17 cells. This is consistent with recent report that IL-23 synergies with Th17 cell differentiation cytokines including IL-6 and TGF-β to induce expression of IL-17.
IL-23 exerts its biological activities by binding to IL-23 receptor (IL-23R). IL-23R comprises an IL-23Rα subunit and an IL-12Rβ1 subunit. When IL-23 binds to IL-23R, it leads to intracellular signaling including phosphorylation of STAT1, STAT3, STAT4 and STAT5. IL-23R is expressed on T-cells, NK cells, monocytes, and dendritic cells and its expression pattern corresponds with the ability of these cells to respond to IL-23.
Human IL-23Rα mRNA is 2.8 kb long and contains 11 exons (NM—144701). The translated full-length IL-23Rα protein is a type-I transmembrane protein (629 amino acids) and contains three (3) structural domains: (1) a signal peptide domain; (2) an extracellular region containing a N-terminal fibronectin III-like domain; and (3) a 253 amino acid residue cytoplasmic domain with three (3) potential tyrosine phosphorylation sites.
Christi Parham et al. first discovered the genomic and structural organization of the IL-23R (composed of an IL-23α subunit and an IL-12Rβ1 subunit). While IL-23 is shown to bind to IL-23R and mediates Jak-STAT cell signaling, Parham explicitly stated their inability to demonstrate human IL-23Rα-Ig and soluble human IL-23Rα-V5-His6 (composed of the entire extracellular domain—amino acids 1-353) as effective antagonists for human IL-23R. Daniel J. Cua et al. disclose treatment methods for multiple sclerosis, neuropathic pain, and inflammatory bowel disorders using antibodies against IL-23 and its receptor. Contrary to Parham's statement, Cua et al. propose using a soluble receptor based on the extracellular region of a subunit of the IL-23 receptor (PCT/US2004/003126) as an antagonist. A recombinant human IL-23Rα Fc chimeric protein is commercially available (R&D Systems) and claimed to have the ability to inhibit IL-23 induced IL-17 secretion in a mouse splenocytes system. It remains unclear as to whether any of these proposed soluble IL-23Rαs may in fact exist in vivo as a naturally-occurring protein, let alone the possibility that such soluble IL-23Rαs may possess ability to block IL-23Rα mediated cell signaling. To this end, Daniel J. Cua et al. (PCT/US2004/003126) failed to provide any evidence that a soluble IL-23 receptor can indeed block IL-23 mediated cell signaling as well as inhibit Th17 producing cells.
Recent evidence suggests that IL-23Rα gene may undergo extensive alternative mRNA splicing. There are at least twenty-four (24) potential gene transcripts for IL-23Rα. From these IL-23Rα alternatively spliced mRNA sequences, there appears at least four (4) deduced putative translated proteins: (1) a short premature IL-23Rα extracellular peptide; (2) a possible soluble form of IL-23Rα lacking a transmembrane/intracellular domain; (3) a full-length IL-23Rα with truncated extracellular region; and (4) a non-responsive membrane bound receptor isoform of IL-23Rα with deletion in intracellular signaling components.
Although many gene transcripts for IL-23Rα (i.e., IL-23Rα splice variants) are suggested, it is important to point out that their actual existence in vivo is presently unknown. There is little information regarding whether any of the deduced IL-23Rα translated products actually exist in vivo, let alone the function of these IL-23Rα protein variants, if any.
Accordingly, there is continuing need for a therapeutic agent that inhibits IL-23 cellular signaling and antagonizes Th17 cell maturation. The present inventors have discovered a naturally-occurring soluble form of IL-23Rα. This soluble form of IL-23Rαlacks the exon-9 or exons-8/9 of the IL-23Rα chain mRNA transcript (e.g., Δ9 and Δ8,9). The present application reveals that recombinant Δ9 and Δ8,9 proteins function to inhibit IL-23 cell signaling and blocks the differentiation of Th17 cells. The recombinant Δ9 and Δ8,9 as well as their protein variant forms of IL-23Rα have the utility application to treat inflammatory bowel diseases such as Crohn's disease.
SUMMARY OF THE INVENTIONIn one aspect, the present invention provides isolated soluble recombinant IL-23Rα protein, wherein said recombinant protein has the following characteristics: a) lacking a transmembrane domain; b) existing as a monomer; and c) having the ability to inhibit IL-23R-mediated cell signaling.
In one aspect, the present invention provides an isolated soluble recombinant IL-23Rα protein that has the capability of inhibiting IL-23R-mediated cell signaling. An exemplary cell signaling event includes the formation of at least one transcriptional factor (phosphorylated) selected from the group consisting of STAT1, STAT2, STAT3, and STAT5. Preferably, the IL-23R-mediated cell signaling is the STAT3 formation.
In one aspect, the present invention provides an isolated soluble recombinant IL-23Rα protein that has the capability of inhibiting IL-23R-mediated cell signaling. An exemplary cell signaling includes the formation of IL17A or IL17F. Preferably, it is the IL17A formation (i.e., production or secretion).
In one aspect, the present invention provides an isolated soluble recombinant IL-23Rα protein that has the ability to inhibit Th17 cell maturation.
In one aspect, the isolated soluble recombinant IL-23Rα protein contains eight (8) amino acids of GLKEGSYC (SEQ ID NO: 9) (See,
In one aspect, the isolated soluble recombinant IL-23Rα protein (Δ9) lacks five (5) amino acids (i.e., DNRGD, SEQ ID NO: 10) (See,
In one aspect, the isolated soluble recombinant IL-23Rα protein (Δ8,9) lacks five (5) amino acids (i.e., DNRGD, SEQ ID NO: 10) and further lacks an extra thirty (30) amino acids (i.e., a total of thirty-five (35) amino acids) due to exon 8 and exon 9 skipping. The missing thirty five (35) amino acid residues locate at the extracellular domain (i.e., C-terminal end of the extracellular domain), and in the proximity of the transmembrane domain (See,
In another aspect, the soluble recombinant IL-23Rα has a total of 356 amino acid residues, after protein translation (See,
The isolated soluble recombinant IL-23Rα (represents a mature protein) has an amino acid sequence set forth in SEQ ID NO: 2. The isolated soluble IL-23Rα protein is encoded by a cDNA having a nucleotide sequence set forth in SEQ ID NO: 1. The isolated soluble IL-23Rα protein (Δ9) (SEQ ID NO: 2) is derived from a human cell, and it may be a recombinant protein.
In another aspect, the isolated soluble recombinant IL-23Rα has an amino acid sequence set forth in SEQ ID NO: 4 (See,
In one aspect, the present invention provides a pharmaceutical composition comprising an isolated soluble recombinant IL-23Rα protein and a pharmaceutical acceptable excipient.
In one aspect, the pharmaceutical composition comprises an isolated soluble IL-23Rα having an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4. The protein may be a recombinant protein.
In one aspect, the present invention provides a method of preparing an isolated IL-23Rα protein, comprising the steps of: a) transfecting a cell with a gene encoding a protein that has an amino acid sequence set forth in SEQ ID NO: 2; b) allowing said transfected cell to produce a recombinant protein; and c) isolating said recombinant protein. The cDNA having a nucleotide sequence set forth in SEQ ID NO: 1. The transfected cell may be a mammalian cell. The recombinant protein has an amino acid sequence set forth in SEQ ID NO: 2.
In one aspect, the present invention provides a method of preparing an isolated IL-23Rα protein, comprising the steps of: a) transfecting a cell with a gene encoding a protein that has an amino acid sequence set forth in SEQ ID NO: 4; b) allowing said transfected cell to produce a recombinant protein; and c) isolating said recombinant protein. The cDNA having a nucleotide sequence set forth in SEQ ID NO: 3. The transfected cell may be a mammalian cell. The recombinant protein has an amino acid sequence set forth in SEQ ID NO: 4.
In one aspect, the present invention provides a method of inhibiting IL-23R-mediated cell signaling in a mammalian cell, comprising the steps of: a) exposing a mammalian cell to a recombinant IL-23Rα protein, wherein said recombinant protein has an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4. Preferably, the mammalian cell is a human cell.
In one aspect, the present invention provides a method of treating a human, comprising the steps of: a) identifying a human inflicted with an inflammatory bowel disease; b) administrating a pharmaceutical composition comprising an isolated recombinant IL-23Rα protein and a pharmaceutical acceptable excipient, The isolated protein contains an amino acid sequence of GLKEGSYC (SEQ ID NO: 9), and has an amino acid sequence set forth in SEQ ID NO: 2. In one aspect, the present invention provides an isolated soluble IL-23Rα protein, wherein said protein has the characteristics of: a) lacking a transmembrane domain; b) existing as a monomer; and c) having the ability to inhibit IL-23R-mediated cell signaling.
In one aspect, the present invention provides a method of treating a human, comprising the steps of: a) identifying a human inflicted with an inflammatory bowel disease; b) administrating a pharmaceutical composition comprising an isolated IL-23Rα protein and a pharmaceutical acceptable excipient, The isolated recombinant protein contains an amino acid sequence of GLKEGSYC (SEQ ID NO: 9), and has an amino acid sequence set forth in SEQ ID NO: 4. In one aspect, the present invention provides an isolated soluble IL-23Rα protein, wherein said protein has the characteristics of: a) lacking a transmembrane domain; b) existing as a monomer; and c) having the ability to inhibit IL-23R-mediated cell signaling.
In one aspect, the present invention provides a method of diagnosing a human subject suspected of suffering from Crohn's disease, comprising the steps of: (a) obtaining a biological sample from a human; (b) determining the level of a soluble IL-23Rα protein in said sample, wherein said soluble IL-23Rα protein (i) lacks a transmembrane domain; (ii) exists as a monomer; and (iii) has the ability to inhibit IL-23Rα-mediated cell signaling; and comparing said IL-23Rα level in said human to the level of said soluble IL-23Rα in an healthy individual, wherein an elevation in said level of said soluble IL-23Rα is indicative of the presence of Crohn's disease.
In one aspect, the present invention provides a method for detecting a soluble truncated IL-23Rα in a biological sample, comprising the steps of: a) obtaining a biological sample; b) incubating said biological sample with a capture reagent immobilized on a solid support to bind said truncated isoform of IL-23Rα, wherein the capture reagent comprises a first antibody that specifically binds IL-23Rα, and a second antibody that specifically binds to the human IL-23Rα; and (c) detecting IL-23Rα bound to said immobilized capture reagent by contacting the bound IL-23Rα with a detectable antibody that binds to human IL-23Rα.
Preferably, the first antibody is a monoclonal antibody, and the second antibody is a polyclonal antibody. Preferably, the first antibody recognizes and binds to a domain that corresponds to the amino acids 318-348. The application is also intended to cover equivalent antibody that recognizes and bind to a domain near the amino acids 318-348 of the C-terminus, and still possess the ability to function as a capture antibody.
The soluble truncated recombinant IL-23Rα lacks a transmembrane domain, and exists as a monomer. The soluble truncated IL-23Rα can inhibit IL-23-mediated cell signaling as well as Th17 cell differentiation. Preferably, the soluble truncated IL-23Rα has an amino acid sequence set forth in SEQ ID NO:2. Preferably, the soluble truncated IL-23Rα has an amino acid sequence set forth in SEQ ID NO: 4.
Preferably, the biological sample is selected from the group consisting of blood and plasma, wherein said biological sample comprising EDTA. More preferably, the biological sample is EDTA-treated plasma.
The following definitions are used for this application:
The term “IL-23R” refers to interleukin-23 receptor. IL-23R is composed of two (2) subunits: IL-23Rα and IL-12Rβ1. The IL-23Rα gene is located on chromosome 1p31.3. The native form of human IL-23Rα mRNA is 2.8 kb long and contains 11 exons (NM—144701). The transcribed mRNA is translated into a full-length protein of 629 amino acids, the sequence of which is listed in NM—144701. The full-length translated IL-23Rαprotein is a type I cytokine receptor and forms with human IL-12Rβ1 to form the heterodimeric IL-23 receptor. Human IL-12Rβ1 also partners with human IL-12Rβ2 to form the cell-surface IL-12 receptor. When bound to IL-23, this protein triggers a series of cell signaling event including activation of Janus kinase 2 (JAK2), and transcription activator STAT3 (i.e., IL-23R mediated cell signaling). IL-23R is present on many immune system cells, including T cells, natural killer (NK) cells, monocytes, and dendritic cells.
The term “soluble IL-23Rα” refers to an IL-23Rα that lacks a transmembrane domain (i.e., contains extracellular domain that encompasses 1-353 amino acid residues of the full-length translated IL-23Rα protein) and thus become soluble in an aqueous medium. A soluble IL-23Rα may be present as monomer or form a homodimer (as is the case for the chimeric molecule where human Fc (from an IgG1 molecule) that is fused with two (2) IL-23Rα molecules. For purposes of this application, the term “soluble IL-23Rα” includes the naturally-occurring truncated IL-23Rα as a result of alternative gene splicing. In particular, it includes Δ9 protein having an amino acid sequence set forth in SEQ ID NO: 2. Also, it includes Δ8,9 protein having an amino acid sequence set forth in SEQ ID NO: 4.
For purposes of this application, the term “Δ9” refers to the naturally-occurring truncated IL-23Rα resulting from IL-23Rα gene splicing. The Δ9 protein has 348 amino acids plus eight (8) novel amino acid sequences unique to Δ9 protein (i.e., a total of 356 amino acids). Amino acid sequence comparison between Δ9 and wild-type IL-23Rα(extracellular domain; 353 amino acids) is provided in
For purposes of this applications, the term “Δ8,9” refers to the naturally-occurring truncated IL-23Rα resulting from IL-23Rα gene splicing. The Δ8,9 protein has 318 amino acids plus eight (8) novel amino acid sequence unique to Δ8,9 (a total of 326 amino acids). Amino acid sequence comparison between Δ8,9 and wild-type IL-23Rα (extracellular domain; 353 amino acids) is provided in
The term “detecting” refers to quantitative measurements of IL-23Rα in a biological sample.
The term “biological sample” refers to a body sample from a mammal, preferably from a human. Biological sample may be obtained from patients inflicted with autoimmune diseases. Biological samples include biological fluids such as serum, plasma, lymph fluid, synovial fluid, amniotic fluid, urine, cerebrospinal fluid, saliva, tissue culture medium, tissue extracts and the like. The preferred biological sample is serum or plasma.
The term “mammal” refers to any animal classified as a mammal, including humans, and animals. Preferably, the mammal is human.
The term “autoimmune disease” refers to a pathological condition in mammals that is typically characterized by an unregulated immune cell activity. Examples of autoimmune include but are not limited to, inflammatory bowel disease, Crohn's disease, asthma and the like. Preferably, the autoimmune diseases are characterized by an increased Th17 activity. The present invention provides an isolated soluble IL-23Rα protein useful for treating inflammatory bowel diseases, such as Crohn's disease. The present invention also provides a composition and method for treating inflammatory bowel diseases.
The term “inflammatory bowel disease” means an inflammatory disease in bowel that involves Th17 cells. Crohn's disease represents an exemplary inflammatory bowel disease.
The term “effective amount” refers to an amount of soluble IL-23Rα sufficient to ameliorate a symptom of a pathological disease (such as Crohn's disease).
The present inventors discovered a hitherto unknown soluble form of a human IL-23Rα receptor (e.g., Δ9 and Δ8,9). Both the Δ9 and Δ8,9 mRNAs are a result of alternative splicing of the IL-23Rα gene that encodes the native IL-23Rα protein. The splice variant Δ9 is missing the exon 9 and does not contain a transmembrane domain and an intracellular domain. In Δ9, Exon 8 joins to Exon 10 and results in the shift of open reading frame and hence generates the novel eight (8) amino acid sequences (i.e., GLKEGSYC, SEQ ID NO: 9). The splice variant Δ8,9 is missing exon 8 and exon 9 and also does not contain a transmembrane domain and an intracellular domain. Δ8,9 also contains the novel eight (8) amino acids of GLKEGSYC (SEQ ID NO: 9). Δ9 mRNA represents up to 20% of human leukocyte IL-23Rα transcript and thus is a major form of IL-23Rα mRNA. Δ8,9 mRNA also is detectable in the Fragment Analysis studies. The Δ9 form of IL-23Rα is secreted as a soluble monomer form and binds to IL-23 in solution. The present inventors further discovered that this soluble IL-23Rα form is capable of blocking IL-23 induced STAT3 phosphorylation and Th17 maturation.
In one embodiment, the present invention provides an isolated truncated IL-23Rαprotein that can be used as an inhibitor of IL-23 cell signaling, in particularly in the context of inflammatory bowel diseases.
It is known that the native form of human IL-23Rα mRNA is 2.8 kb long, with 11 exons (NM 144701). This mRNA is translated into a type-I transmembrane protein of 629 amino acids. The native human IL-23Rα protein comprises an extracellular domain that contains 353-residue extracellular domain that includes a signal peptide, an N-terminal fibronectin-III-like domain, as well as a 253-residue cytoplasmic domain with three potential tyrosine phosphorylation sites. Genetic studies have suggested an association the IL-23Rαlocus with protection/susceptibility in autoimmune inflammatory disorders, although the exact mechanistic basis remains elusive.
The present inventors have unexpectedly discovered a novel soluble truncated IL-23Rα. The present invention extends our previous findings that IL-23Rα mRNA undergoes extensive alternative splicing—resulting in twenty-four (24) different potential transcripts. Four different classes of putative translation products could be deduced from these alternatively spliced mRNA sequences: (i) short premature IL-23Rα extracellular peptides; (ii) soluble forms of IL-23Rα lacking transmembrane/intracellular domains; (iii) full-length IL-23Rα with a truncated extracellular region; and (iv) a membrane bound receptor isoform of IL-23Rα that lacked likely intracellular signaling components.
Using Fragment Analysis, the present inventors surprisingly discovered that there are six (6) alternative mRNA splice forms in human leukocytes. One of the forms (i.e., Δ9) represents the majority alternative mRNA splice form. Δ9 is found to be soluble and exists as monomer, and it has the ability to bind IL-23 and inhibit the generation of functional human Th-17 cells in vitro. Different from that of the native IL-23Rα protein, the present soluble truncated IL-23Rα lacks a transmembrane domain and contains 356 amino acids. Another form (i.e., Δ8,9) also share the common features as Δ9 (e.g., soluble monomer and ability to block IL-23R mediated cell signaling).
According to the present invention, a soluble truncated IL-23Rα form (i.e., Δ9 protein) contains a unique eight (8) amino acid sequence (GLKEGSYC, SEQ ID NO: 9) at its C-terminus, due to the exon 8 and exon 9 skipping. When analyzed under conditions of a reducing gel electrophoresis, the molecular weight of the protein is approximately ˜60 kDa. The soluble truncated IL-23Rα protein (Δ9) corresponds to the N-terminal fragment of IL-23Rα lacking the transmembrane domain and has 356 amino acids (with 348 amino acids correspond to that of the native IL-23Rα, plus the eight (8) unique amino acid sequence of SEQ ID NO: 9)). The amino acid sequence of this particular soluble truncated IL-23Rα (i.e., Δ9 protein) is set forth in SEQ ID NO: 2.
According to the present invention, another soluble truncated IL-23Rα (i.e., Δ8,9 protein) also contains a unique eight (8) amino acid sequence (GLKEGSYC, SEQ ID NO: 9) at its C-terminus due to the alternative translation reading frame on exon 10. When analyzed under conditions of a reducing gel electrophoresis, the molecular weight of the protein is approximately ˜60 kDa. The soluble truncated IL-23Rα protein corresponds to the N-terminal fragment of IL-23Rα lacking the transmembrane domain and has 326 amino acids (with 318 amino acids correspond to that of the native IL-23Rα plus the eight (8) unique amino acid sequence of SEQ ID NO: 9). The amino acid sequence of the soluble truncated IL-23Rα (i.e., Δ8,9 protein) is set forth in SEQ ID NO: 4.
In one embodiment, the present invention provides an isolated IL-23Rα protein that includes the protein selected from any of the following protein, an isolated protein of a truncated human IL-23Rα capable of inhibiting IL-23-mediated cell signaling; a recombinantly produced truncated human IL-23Rα; or a purified recombinant human truncated IL-23Rα having an amino acid sequence set forth in SEQ ID NO: 2 and SEQ ID NO: 4.
The soluble truncated IL-23Rα exists as a monomer and contains a unique eight (8) amino acid sequence. In one embodiment, the soluble IL-23Rα is detected in cultured media and can be recombinantly produced. The isolated truncated IL-23Rα protein has therapeutic value to allelviate inflammatory bowel diseases including Crohn's disease.
In a preferred embodiment, the present invention provides a recombinant soluble IL-23Rα, which has the amino acid sequence set forth in SEQ ID NO: 2 and SEQ ID NO: 4.
The present invention provides an isolated nucleic acid molecule encoding a truncated human IL-23Rα protein lacking a transmembrane domain. In one embodiment, the isolated nucleic acid molecule is a DNA molecule, preferably the isolated DNA is genomic DNA. In another embodiment, the isolated DNA molecule is a cDNA molecule. In one embodiment, the isolated nucleic acid molecule is an RNA molecule. In an embodiment, the isolated nucleic acid molecule encodes a human IL-23Rα having an amino acid sequence set forth in SEQ ID NO: 2, wherein the nucleotide sequence of the isolated DNA molecule is set forth in SEQ ID NO: 1. In an embodiment, the isolated nucleic acid molecule encodes a human IL-23Rα having an amino acid sequence set forth in SEQ ID NO: 4, wherein the nucleotide sequence of the isolated DNA molecule is set forth in SEQ ID NO: 3.
The present invention provides a recombinantly produced human IL-23Rαlacking a transmembrane domain. The present invention provides a purified recombinant human truncated IL-23Rα having the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4.
In one embodiment, the present invention provides the expression of the DNA sequences disclosed herein. As is well known in the art, DNA sequences may be recombinantly expressed by operatively linking the sequences to an expression control sequence in an appropriate expression vector; and expressing that linked vector via transformation in an appropriate unicellular host. Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence. A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and Synthetic DNA sequences. Suitable vectors include pcDNA 3.3.Topo, pcDNA 3.1, pCI, pSI, pTARhET, pPMR, pTK-Hyg and the like.
In one embodiment, a host cell contains the vector comprising the polynucleotides of the present invention. Exemplary host cell includes mammalian cells. Various cells strains include, for example, 293T, CHO, COS and the like.
It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the IL-23Rα cDNA sequences of this invention. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered. In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products. Considering these and other factors, a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention in large scale animal culture.
For recombinant expression of the various proteins used in this application, genes encoding the various proteins of interest can be conveniently inserted into a cloning vector and the vector containing the gene of interest is transfected into a suitable host cell for protein expression. Various publicly available vectors may be used. For example, vectors may include a plasmid, cosmid, viral particle, or phage. Examples of vectors included pcDNA 3.3.Topo, pcDNA 3.1, pCI, pSI, pTARhET, pPMR, pTK-Hyg and the like. Vector components generally include, but are not limited to, an origin of replication, a selectable marker gene, an enhancer element, a promoter, and a transcription termination sequence and a poly-A+ signal. Construction of suitable vectors containing one or more of these components as well as the gene of interest employs standard ligation techniques which are known to the skilled artisan.
Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that confer resistance to antibiotics, e.g., ampicillin, neomycin, methotrexate, or tetracycline and puromycin.
Examples of suitable selectable markers for mammalian cells include those that enable the identification of cells competent to take up the antigen-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980).
A number of promoters can be used in order to enhance the expression of the gene of interest. In one embodiment, a promoter can be employed which will direct expression of a polynucleotide of the present invention in 293T cells. Other equivalent transcription promoters from various sources are known to those of skill in the art. Exemplary promoters include SV40 early, CMV, HSV TK, EF-1a and the like.
A promoter may be operably linked to the protein-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known.
Transcription of a DNA encoding the gene of interest by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 basepairs, that can act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5′ or 3′ to the 15-kDa coding sequence, but is preferably located at a site 5′ from the promoter.
Expression vectors used in mammalian cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5′ and, occasionally 3′, untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding Δ9 protein.
The nucleic acid (e.g., cDNA or genomic DNA) encoding recombinant Δ9 or Δ8, 9 of the present invention may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. For example, DNA encoding Δ9 (e.g., SEQ ID NO: 1) or Δ8, 9 (e.g., SEQ ID NO: 3), such as full-length Δ9 protein (SEQ ID No.2) or Δ8, 9 protein (SEQ ID No. 4) may be inserted into a replicable vector for cloning and for expression of full-length Δ9 or Δ8, 9 protein or fragments thereof. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
Host cells are transfected with expression or cloning vectors described herein for protein production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991).
Methods of eukaryotic cell transfection transformation are known to the ordinarily skilled artisan, for example, CaCl2, Ca2PO4, liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., or electroporation is generally used for prokaryotes. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. However, other methods for introducing DNA into cells, such as by nuclear microinjection and electroporation may also be used. For various techniques for transforming mammalian cells, See Keown et al., Methods in Enzymology, 185:527-537 (1990). The particular selection of host/cloning vehicle combination may be made by those of skill in the art after due consideration of the principles set forth without departing from the scope of this invention (See, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual 2nd edition, 1989, Cold Spring Harbor Press, NY).
Recombinant gene expression may be measured in a sample directly, for example, by conventional Northern blotting, RT-PCR or quantitative real time RT-PCR (qRT-PCR) to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)).
Recombinant gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to Δ9 or Δ8, 9 DNA and encoding a specific antibody epitope.
It may be desired to purify recombinant Δ9 or Δ8, 9 from host cell proteins. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; metal chelating columns; or a specific antibody column to bind epitope-tagged forms of the protein of interest (e.g., nickel columns to bind His-tagged proteins, anti-HA columns to bind HA-tagged proteins, or anti-FLAG columns to bind FLAG-tagged proteins). Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular antigen produced.
The present invention further provides a pharmaceutical composition for alleviating inflammatory bowel disease in a subject which comprises a purified protein of the invention and a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carrier encompasses any of the standard pharmaceutical carriers. The pharmaceutical composition may be constituted into any form suitable for the mode of administration selected. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions. In an embodiment, the pharmaceutical composition is suitable for administering a nasal route to a subject. An example includes aerosolized solution.
IL-23 is a heterodimeric cytokine belonging to IL-6 helical cytokine family. It is composed of two disulfide-linked subunits, p19 and p40. p40 is also a component, with p35, of IL-12, a cytokine in this same family. This allowed the relative contribution of IL-23 and IL-12 to autoimmune disease to be clarified, when the p19 and p35 subunits were targeted in gene knockout studies. IL-23p19, but not IL-12p35, deficient mice were resistant or showed decreased pro-inflammatory responses in experimental autoimmune encephalomyelitis, inflammatory bowel disease and collagen-induced arthritis. Thus, IL-23 (and by inference, its receptor) became established as an important component of autoimmune inflammatory disorders.
Th17 cells represent a novel, distinct subset of CD4′T-helper cells. Differentiation of naive human CD4+ T cells to Th17 cells is recognized to have critical functions in autoimmune disease models in mice. Evidence indicates that mice deficient in p19, the unique subunit of IL-23, demonstrated resistance in different autoimmune disease models, mainly because of the absence of T cells producing IL-17 (i.e., Th17 cells). Differentiation of Th17 cells in vivo requires the presence of IL-23, which is secreted by activated antigen-presenting cells. It is well that IL-23 per se cannot induce the differentiation of naive CD4+ T cells into Th17 cells in vitro, but may synergies with Th17 cell differentiation agents including IL-1, IL-6 and TGF-β to induce expression of IL-17 cytokine According to one embodiment, the present invention provides a therapeutic application of a soluble truncated IL-23Rα (e.g., Δ9). Hence, Δ9 has the capability of inhibiting the cell signaling mediated by IL-23 as well as inhibiting the maturation of Th17 cells. The present inventors believe that Δ9, when administered, would behave as an inhibitor to inhibit the IL-23-mediated cell signaling and Th17 maturation, and thus alleviating the development and progression of Th17-associated diseases such as inflammatory bowel diseases that include Crohn's disease.
In one embodiment, the present invention provides Δ9 that represents a soluble form of the IL-23 a receptor extracellular domain by transiently transfect the Δ9 expression construct (SEQ ID NO: 1) into a mammalian expression cell system (e.g., 293-T cells; human embryonic kidney fibroblast cells).
In one embodiment, the present invention provides Δ8, 9 that represents a soluble form of the IL-23a receptor extracellular domain by transiently transfect the Δ8,9 gene (SEQ ID NO: 3) into a mammalian expression cell system (e.g., 293-T cells; human embryonic fibroblast cells).
In one embodiment, the Δ9 or Δ8, 9 genes may be stably transfected into a mammalian expression cell system using standard protocols as recognized by one of ordinary skill in the art.
In one embodiment, the present invention provides an ELISA to aid detecting the circulating level of the soluble truncated IL-23Rα protein. One of ordinary skill in the art would recognize the use of commercially-available antibodies in the present developed Δ9 ELISA. Using an ELISA, it is demonstrated that Δ9 is present at low levels in the periphery of healthy individuals. Similarly, the present inventors believe that Δ8,9 are present in patients suffering from inflammatory bowel diseases. Soluble cytokine receptors may be generated by several mechanisms, including proteolytic cleavage of receptor ectodomains, alternative splicing of mRNA transcripts or transcription of distinct genes. The present inventors believe that Δ9 (and Δ8,9) present in the circulation is solely a result of alternative splicing of the native IL-23Rα mRNA. Given the human genome project is completed, it is believed that it is highly unlikely that there is a distinct gene encoded for a soluble form of IL-23Rα chain.
In one embodiment, the present invention provides a therapeutic application of the soluble truncated IL-23Rα. More particular, the present inventors have discovered that Δ9 or Δ8,9 are effective in inhibiting IL-23-mediated cell signaling. In another embodiment, the present invention provides the use of Δ9 or Δ8,9 in inhibiting STAT formation. In yet another embodiment, the present invention provides the use of Δ9 or Δ8,9 to inhibit Th17 cell maturation. The present finding is in great contrast with the original report by Parham et al. who described the human and mouse IL-23 receptor, despite their binding by their external domain Fc and V5-HIS6 constructs. According to Parham, “neither [human and mouse IL-23 receptor) could act as effective antagonists.” The present invention provides a naturally-occurring form of Δ9 (or Δ8,9) form can inhibit STAT3 phosphorylation and Th-17 cell differentiation in an in vitro human leukocyte assay, starting from naive CD4+ T cells. Notably, the present finding cannot be explained by Δ9 or Δ8,9 signaling via IL-12. Our data showed that Δ9 and Δ8,9 binds to IL-23 but not its sister cytokine IL-12, thus further demonstrated that this was via the p19, not the p40, component.
In one embodiment, the present invention provides a soluble truncated IL-23Rα that inhibits the secretion of IL-17A and IL-17F. IL-23 is the key element in the final stages of Th-17 phenotypic maturation. In the present Th-17 maturation assays, naive CD4+ T cells were successfully differentiated to Th17 cells, based on their up-regulation of RORγt (the signature transcription factor for this cell sub-type), and secretion of IL-17A and IL-17F. The induction of IL-17A&F expression was abolished when Δ9 (or Δ8,9) was present is consistent with the observation that Δ9 did not affect changes in RORγt expression level. These results reinforce our hypothesis that Δ9 (or Δ8,9) can function as a naturally-occurring specific inhibitor of IL-23 which has the ability to regulate Th-17 cell development.
In one embodiment, the present invention provides that Δ9 (and Δ8,9) can suppress the secretory phenotype of human Th17 cells, demonstrating the existence of a novel regulatory mechanism for human Th17 cells. The present findings have practical utility for the therapeutic application of Δ9 and Δ8,9. Specifically, Δ9 or Δ8,9 may be used as a therapeutic agent for treating human Th17-dependent conditions such as Crohn's Disease, asthma and psoriasis. Many attempts have been made based on the premise that IL-23 is a target for anti-inflammatory therapies, particularly in the intestine; the present finding adds that Δ9 or Δ8,9 may represent a novel tool in this process.
The present invention provides a method of treating or alleviating inflammatory bowel disease in a subject which comprises administering to the subject an amount of any of the aforementioned compositions comprising the invented purified proteins, said amount effective to block IL-23 cell signaling in the subject. A subject may be a mammal, for example, a human.
The present invention will be better understood from the following experimental studies. One of ordinary skill in the art would readily appreciate that the specific methods and results discussed therein are not intended to limit the invention. The experimental studies merely serve illustrative purposes, and the invention is more fully described by the claims which follow thereafter.
Experimental Studies Example 1 Multiple Potential Splice Variant Forms of IL23Rα in Human LeukocytesIn a previous study, we reported the identification of twenty-four (24) potential IL-23Rα “deletion” splice variants and one (1) “insertion” splice variant in human leukocytes (Genes and Immunity (2008) 9: 631-639 & 566-569, 2008). The expression level of these IL-23Rα splice variants in vivo was unclear because of the lack of a reliable quantitation assay which permits the measurement of these variant transcripts in vivo. However, it was noted that a majority of these IL-23Rα splice variants introduce early termination codons to the open reading frames immediately after the alternative splicing event, which may produce premature proteins with only short peptides of the IL-23Rα. Lacking such critical information, the physiological and pathological roles of their translated proteins, if any, are unknown.
Example 2 Determination of Six (6) IL-23R Splice Variants in Human LeukocytesIn the present study, we specifically addressed the issue if these IL-23Rα splice variants may be present in vivo. To do so, we performed a Fragment Analysis to semi-quantitatively measure the mRNA expression level of these IL-23Rα isoforms in a single PCR reaction using a Beckman CEQ8000 machine. We compared quantitatively the individual human IL-23Rα splice variant forms relative to the full-length (wild-type, “wt”) IL-23Rα form (
Human leukocytes (i.e., PBMC) were isolated and used as a cellular model to examine the expression of different IL-23Rα isoforms. RNA was extracted (using Stratagene RNA mini-prep kits) from the isolated PBMC and its concentration was measured in Nanodrop. Two (2) micrograms (μg) of RNA was reversely transcribed into cDNA. A pair of gene specific IL-23R primers (P5) and (P6), which was fluorescent labeled (P6-D3), was designed to amplify IL-23R isoforms by PCR (see “Materials & Methods” section, infra, for primer sequence information). Amplified products were denatured, run on the CEQ8000 machine and separated by size. Peaks were assigned to the corresponding variants based on their size. The fluorescent signal represented the level of expression.
Using this assay, we found that not all of the potential IL-23Rα isoforms are detectable. To our surprise, we routinely detected only six (6) IL-23Rα splice mRNA variants (See,
Of the six (6) human IL-23Rα mRNA variant forms, one constituted a single major alternative splice variant form of IL-23Rα (i.e., Δ9) in the leukocyte cells tested. While the wild-type occupies ˜68% of the total population of IL-23Rα, Δ9 has ˜12% (
The Δ9 splice mRNA variant is generated when the deletion of exon-9 results in a frame-shift on splicing of exon-8 to exon-10 (
In this study, we identified the Δ9 mRNA variant by PCR amplification using mRNA extracted from the human leukocytes. The RT-PCR products were then cloned into a plasmid vector (i.e., TOPO TA vector PCR2.1 from Invitrogen (Calrsband, Calif.)). Colony PCR was applied using M13 forward and M13 reverse primers located on either side of the TA cloning sites on the vector to screen the colonies containing PCR insert according to the manufacture's protocol. We performed gene sequencing reaction and obtained the sequence information of the PCR insert.
The translated Δ9 protein has 356 amino acids and notably contains a unique eight (8) amino acid sequence at the C-terminus (
In this series of study, we sought to recombinantly express the Δ9 variant in order to obtain the recombinant Δ9 protein. To do so, we prepared both the wild-type IL-23Rα and Δ9 variant expression constructs.
a) cDNA and Construction of Expression Plasmid
The cDNAs of the wild-type IL-23Rα and Δ9 variant were obtained by the PCR amplification (see “Materials & Methods”).
We inserted a “FLAG” sequence to the reverse primers to tag the recombinant protein for purposes of ease of purification and detection. The PCR products were sub-cloned into the pcDNA3.3 TOPO vector, using TA cloning kit from Invitrogen (Carlsbad Calif.) (see Method). The nucleotide sequences for the wild-type IL-23Rα and Δ9 variant expression constructs were verified by the DNA sequencing. Both forms were tagged with the “FLAG” sequence at the C-terminus of expressed protein.
b) Mammalian Expression of Recombinant Proteins
We performed transient transfections with FLAG-tagged wild-type or Δ9 expression constructs (i.e., mammalian expression vector containing coding nucleotide sequences of interest) in 293T cells using FuGENE HD following the manufacture's protocol (Roche) (see “Materials & Methods”).
Cellular lysates and culture media were harvested 48 hours post-transfection (see “Materials & Methods”). We detected the recombinant protein expression by the immunoblot using Anti-Flag M2 antibody (Sigma). Both expression constructs showed similar intra-cellular expression levels (using anti-FLAG Western blotting) in the transient transfection assay performed in the 293T cells. However, we only detected Δ9 protein variant in the culture medium, indicating that it was efficiently processed for secretion (
Under reducing and denatured gel electrophoresis (SDS-PAGE), the “Flag” tagged Δ9 protein variant exhibits ˜65 kDa molecular weight (
c) Purification of Recombinant Δ9 Protein from the Transient Transfected 293T Cells
We transfected a mammalian cell (i.e., human embryonic kidney fibroblast cell; 293T cell) with either the control expression vector alone or the expression vector carrying the Δ9 coding nucleotide sequence (i.e., SEQ ID NO: 1). Cell lysates and culture media were prepared and collected for the purification purpose (see “Materials & Methods”).
Cells were lysed and cellular lysates were prepared. Δ9 protein was then immuno-purified using an anti-Flag M2 affinity gel (Sigma). The immuno-precipitated Δ9 protein was eluted by incubating with excess amount of Flag peptide (see Method). The purity of Δ9 protein was assayed by SDS-PAGE gel followed by Coomassie-blue staining.
No specific band was detected from 293T cell lysate transfected with empty vector, whereas Δ9 protein purified from the cell lysate transfected with Δ9 expression plasmid showed multiple bands (
Cytokine receptor (i.e. IL-23Rα) is known to undergo N-glycosylation modification (See Example 12). It is possible that not all the intracellular Δ9 IL-23Rα proteins are fully N-glycosylated, resulting in a heterogeneous population of purified Δ9 IL-23Rα.
We also performed the purification experiment using the culture media from the 293T cells transfected with empty vector or Δ9 expression plasmid. No protein was detected from 293T cell lysate transfected with empty vector, whereas the purified Δ9 protein from secreted source (culture media) showed a homogenous population as a single band of ˜65 kDa in size (
To determine whether the Δ9 protein variant form occurs naturally, we developed an ELISA assay to detect soluble human IL-23Rα. In the following series of studies, we sought to detect Δ9 protein in culture cell supernatants. We also sought to determine if the Δ9 protein is present in the blood circulation of healthy individuals and compared that with patients suffering from inflammatory bowel diseases (e.g., Crohn's disease). In summary, we have established that a soluble variant of the human IL-23Rα exists that is generally present at low levels in the circulation of healthy individual, but the level increases with Crohn's patients.
ELISA Development
Using the recombinant expressed IL-23Rα proteins in the 293T cells (see “Materials & Methods” for the construction of expression plasmids), we proceeded to develop an ELISA sandwich system. The ELISA system allows detection of the soluble form of human IL-23Rα (Δ9). In this ELISA system, two anti-hIL-23Rα antibodies are required, each recognizing different epitopes on IL-23Rα. The cell lysates obtained from the transient transfection experiment were used to examine the antibody specificity and epitope mapping.
a) Capture Antibody
Mouse anti-human IL-23Rα was used in the immunoblot assay (
Because this antibody fails to detect Δ8 and Δ8,9 proteins, it is speculated that the antibody recognizes the C-terminal region of extracellular domain encoded by exon 8.
In addition to the commercially available mouse anti-hIL-23Rα antibody (R&D Systems), we also prepared different mouse monoclonal antibodies targeted against human IL-23Rα protein (i.e., amino acid residues 116-129). Synthetic peptides covering this region were used as antigen and injected into mice to prepare monoclonal antibodies. Several hybridoma cells were generated. We selected four (4) hybridoma cells and obtained purified monoclonal antibodies from these hybridoma supernatants. All these hybridomas show avid binding (i.e., high affinity) to the peptide antigen (i.e., amino acid residues 116-129).
The four (4) hybridoma clones were identified as 2C8E10, 2C8C4, 3A5C11 and 3A5D11. Monoclonal antibodies secreted by these hybridoma cells were further purified using Protein A resin (standard protocol). The purified monoclonal antibodies were tested in two (2) different validation assays: namely (i) immunoprecipitation and (ii) ELISA.
All four (4) monoclonal antibodies were shown to immunoprecipitate Δ9 protein. Immunoprecipitation was performed using standard protocol (See “Materials & Methods).
Two (2) of the purified monoclonal antibodies from hybridoma cells (i.e., 3A5C11 and 3A5D11) were tested using our ELISA. Instead of using the commercially available mouse anti-hIL-23Rα antibody from R&D as the capture antibody, we used our purified monoclonal antibodies (i.e., 3A5C11 and 3A5D11) in the ELISA to measure the amount of soluble human IL-23Rα. We found that both of our monoclonal antibodies are capable of capturing soluble human IL-23Rα similar to the commercially available mouse anti-hIL-23Rα antibody (See Table below).
b) Detection Antibody
Goat anti-human IL-23Rα was used as a detection antibody. The goat anti-human IL-23Rα is preferably in biotinylated form.
We examined the specificity of the biotinlyated goat anti-human IL-23Rα (
As such, the mouse and goat anti-human IL-23Rα antibodies were used as a “match antibody pair” in the ELISA. The mouse antibody was used as the capture antibody because of its high sensitively to Δ9, whereas the biotinlyated goat antibody was used for detection.
c) ELISA Sandwich
The captured Δ9 IL-23Rα was then detected by a biotinlyated goat anti-human IL-23Rα antibody. The goal anti-human IL-23Rα antibody recognizes a different epitope than that of mouse anti-human IL-23Rα antibody.
d) Detection System
The antibody-antigen sandwich was detected by streptavidin conjugated with horseradish peroxidase (HRP), which specifically binds biotin on the detection antibody. The peroxidase activity (representing the level of Δ9) was measured by addition of tetramethylbenzidine (TMB) substrate. The color intensity was in direct proportion to the amount of the bound IL-23Rα. Color development was stopped (by adding 1 M H2SO4) and the intensity of the color was measured at optical density (OD) 450 nm on a microtiter plate reader.
Example 7 ELISA Confirms Δ9 is a Secretary Proteina) Control Human Subjects
b) Patient with Crohn's Disease
We next examined whether Δ9 protein was capable of binding to IL-23. Given the sharing of the p40 chain between IL-23 (p19+ p40) and the related cytokine IL-12 (p35+p40), it was also important to establish if Δ9 was specific for IL-23. Culture medium from 293T cells transfected with either empty vector or FLAG-tagged Δ9 expression construct was concentrated and incubated with 200 ng of either IL-23 or IL-12, then immunoprecipitated with anti-FLAG M2 affinity gel (See “Materials & Methods”).
The immunoprecipitate was subjected to Western blotting and Δ9 or IL-23/12 was visualized with either anti-hIL23Rα or anti-hIL-12/23p40. M2 gel alone was incapable of pulling down IL-23, whereas IL-23 was detected in the precipitate when Δ9 protein was present in the precipitation reaction (
While both experiments confirmed that Δ9 had successfully been precipitated with anti-FLAG, only the incubation of Δ9 with IL-23 allowed visualization of the p40 band, demonstrating that Δ9 specifically binds IL-23 free in solution, but will not bind IL-12 (
We performed deletion analysis to identify a possible minimal domain or region that is required by the Δ9 protein that binds to IL-23 cytokine The extracellular domain of full length IL-23Rα consists of a total of 353 amino acids (i.e., amino acid residues 1-353) (
Similarly, Δ8,9 protein consists of a total of 318 amino acids from extracellular domain of IL-23Rα (i.e., amino acids 1-318) plus the same novel eight (8) amino acids generated through alternative open reading frame used when exon 7 and exon 10 were joined (See,
In addition, we also prepared two (2) more IL-23Rα deletion mutants; namely, 1-250 mutant and 1-200 mutant. These deletion mutants were generated by PCR (See,
We developed a competitive ELISA to further examine the ability of the deletion protein mutants (i.e., Δ9, Δ8,9 and 1-250 mutant) to compete (i.e., interfere) the binding of IL-23 cytokine to the full-length extracellular domain of IL-23Rα (See, “Materials & Methods”). Recombinant IL-23Rα-Fc fusion protein from R&D (2 μg/ml) was coated on the ELISA plate. IL-23 cytokine (50 ng) was added in the absence or presence of the deletion protein mutants as competitors.
In the absence of Δ9, Δ8, 9 or 1-250 mutant, IL-23 cytokine effectively bound to the IL-23Rα-Fc fusion protein coated on the plate surface (
The mature form of Δ9 variant comprises some 333 amino acids (i.e., 356 amino acids minus the signal peptide of 23 amino acids), predicting a size of 41 kDa. Its observed size, however, was consistently around 65 kDa (
Recombinant IL-23 (200 ng) was added to PNGase F treated or untreated Δ9 in the immunoprecipitation reaction. Interestingly, removing the glycosyl component of Δ9 clearly reduced its capacity to bind IL-23 (
On the cell surface, human IL-23Rα combines with human IL-12Rβ1 to form the heterodimeric IL-23 receptor. Human IL12Rβ1 also partners with human IL12Rβ2 to form the cell-surface IL-12 receptor. We wanted to know whether Δ9 could link to human IL-12Rβ1 via IL-23, or indeed bind it directly. Soluble, recombinant HIS-tagged hIL-12Rβ1 (1 μg) was spiked into concentrated FLAG-tagged Δ9-containing 293T supernatant in the presence or absence of IL-23 (200 ng). Immunoprecipitation with anti-FLAG was performed and the Western blots analysed with anti-HIS, anti-hIL-12/23p40 or anti-hIL-23Rα to visualize shIL-12Rβ1, the IL-23 p40 subunit or Δ9, respectively. Δ9 does not bind directly to human IL-12Rβ1 (
However, when IL-23 was added to the binding assay, immunoprecipitation with anti-FLAG allowed visualization of all three reactants: Δ9, IL-23 (p40) and human IL-12Rβ1, indicating that Δ9 forms a complex with human IL-12Rβ1 through binding to IL-23, thus mimicking the cell-surface receptor (
Next, we tested the ability of Δ9 to interfere with the natural biological functions of human IL-23, in vitro. Signaling through the IL-23 receptor primarily triggers the phosphorylation of STAT3; which is essential to the maturation of Th17 cells. We incubated freshly-isolated human PBMCs with 10 ng/mL IL-23 and examined the phosphorylation of multiple STATs (See “Materials & Methods”). As expected, the greatest influence of IL-23 was on STAT3 (
In the presence of 5 ng/mL IL-23, phospho-STAT3 was elevated by 4.8 fold; supernatants from 293T-cells transfected with expression construct containing the full-length (wt) IL-23Rα transcript showed a slight enhancement of this (7-fold elevation of phospho-STAT3 compared with no IL-23 added). However, supernatants from 293T cells transfected with the Δ9 expression construct effected a marked reduction of phospho-STAT3, below the level of IL-23 alone, demonstrating a notable inhibition of IL-23's function on human leukocytes (
To confirm that this inhibition was indeed due to Δ9, we purified recombinant Δ9 protein from the secreted source to apparent homogeneity (
a) Maturation of Th17 Cells
IL-23 is key to the function of Th17 cells, although by itself it is incapable of inducing the differentiation of these cells in vitro, from a starting population of naive human CD4+ T-cells. However, the ability of Δ9 to inhibit IL-23 signaling suggested that it would also inhibit the functional maturation of human Th17 cells.
We purified human CD3+CD4+CD45RA+ cells (“naive CD4+ T-cells”) by negative selection (using magnetic beads coupled with specific bound antibodies against the cell surface markers.
We differentiated the isolated cells to Th17 cells in vitro, using the protocol as illustrated in the
We used the expression levels of the four (4) major T-cell transcription factors as indicator for the T-helper (Th) cell differentiation (i.e. GATA3 (Th1), T-bet (Th2), Foxp3 (Treg) and RoRγt (Th17)). Bead stimulation of naive CD4+ T-cells in the absence of cytokine permitted the expression of these transcription factors, GATA3, T-bet, Foxp3 and RoRγt (
Terminal maturation of the Th17 phenotype by IL-23 was demonstrated by the enhanced expression of IL-17A, IL-17F mRNA in the presence of IL-23 (
b) Δ9 Inhibits IL-17A and IL17F
Addition of Δ9 alone to the Th17 cocktail failed to induce the mRNA expression of IL-17A or IL-17F, confirming its lack of stimulatory activity (
Materials and Methods
Fragment Size Analysis of Human IL-23Rα (HuIL23Rα) Splice Variants
Purified RNA from mitogen-stimulated PBMCs was reverse-transcribed into cDNA and PCR was carried out with forward primer (5′ AATGCTGGGAAGCTCACCTACATA 3′) (SEQ ID NO: 5) and reverse primer (5′ D3-GCTTGTGTTCTGGGATGAAGATTTC 3′) (SEQ ID NO: 6), which was fluorescent labeled with the “D3” dye. The amplified product was denatured and analyzed in the Beckman CEQ8000 using their Fragment Analysis Program, calibrated with DNA size standard marker kit 600 (0.5 μl/reaction; Beckman) and custom-made D1 labeled 600-1200 size marker (1 μl/reaction; Bioventures, Inc). Peaks were assigned to corresponding HuIL23Rα spliced variants based on their size. The fluorescent signal represented the mRNA transcript level.
Construction of Expression Constructs
Human wild-type IL-23Rα was amplified from human peripheral blood mononuclear cells (PBMC)'s cDNA using the following primer pair by Pfx high fidelity DNA polymerase (Invitrogen).
The amplified PCR product was run on agarose gel and purified using DNA gel purification kit from Qiagen. The gel purified PCR product was cloned into pcDNA3.3 using TOPO TA cloning kit from Invitrogen. The ligated product was transformed into Top10 competent cell (Invitrogen). The transformed competent cells were selected using LB plate containing ampicillin for 16 hours at 37° C. The ampicillin resistant clones were cultured in 2 mL of LB medium with ampicillin for 16 hours at 37° C. DNA was extracted from the bacteria culture using DNA mini-preparation kit from Qiagene. The DNA was then validated by restriction enzyme digestion and sequencing. The confirmed expression construct was used to prepare high quality DNA for transfection using DNA maxi-preparation kit from Qiagene. The purified DNA was quantified by Nano-drop (Thermo Scientific).
The expression constructs of pΔ11, Δ8, Δ9 and Δ8,9 were made by the same approach except using different primer sets described below.
Generation of Expression Constructs
Expression construct of wild-type IL-23R (WT) was generated by PCR using Pfx DNA polymerase (Invitrogen). Forward primer (5′ ATGAATCAGGTCACATTCAATG 3′) (SEQ ID NO: 11) and reverse primer (5′ CTACTTGTCATCGTCGTCCTTGTAATCCTTTTCCAAGAGTGAAATCCTATTG 3′) (SEQ ID NO: 12) were used to amplify wild-type IL-23R from PBMCs cDNA. The amplified PCR product was treated with Taq polymerase to add 3′-A overhang to each end of PCR. The gel-purified product was then subcloning into mammalian expression plasmid using the pcDNA3.3 TOPO TA Cloning kit from Invitrogen. The correct expression construct was subjected to validation by sequencing.
Constructions of pΔ11, Δ9 and Δ89 expression plasmids were performed using the same method except pcDNA3.3 IL-23R WT was used as PCR template. Difference primer sets were also used as shown in the following:
Construction of Δ8 expression plasmid was performed by PCR overlap extension. Two fragments, fragment 1: Translation start to Exon 7 and fragment 2: Exon 9 to Translation stop, were amplified using the following primer pairs.
Two amplified fragments (1 and 2) were then joined together by overlapping extension. The final combined fragment was sub-cloned into pcDNA3.3 TOPO expression vector.
Isolation and Culture of Human PBMCs and Immune Cells
Peripheral blood mononuclear cells were isolated from heparinized whole venous blood of healthy donors by density gradient centrifugation using Ficoll-Paque (Sigma-Aldrich, St Louis, Mo., USA) according to the manufacture's instructions. Blood was purchased as anonymous buffy coats from New Jersey blood transfusion service with no donor identifying details. Isolated PBMCs were maintained in RPMI-1640 medium (Invitrogen-Gibco, Carlsband, Calif., USA) supplemented with 10% heat-inacticated fetal bovine serum (Invitrogen-Gibco) and 1 mM glutamine (Invitrogen-Gibco). Distinct immune cell populations such as B-cells, T-cells, NK-cells and monocytes were positively isolated from PBMCs by EasySep magnet kits (StemCell Technologies). In the stimulation study, isolated PBMCs were recovered for 2 hours at 37° C. in the 10% FBS/RPMI-1640 medium.
Fragment Analysis
PBMCs were cultured for 72 hours and total RNA was isolated by ‘Absolutely RNA’ miniprep kit (Stratagene) following the manufacturer's instructions. Purified RNA was reverse-transcribed into cDNA using AffinityScript cDNA synthesis kit (Stratagene). PCR was carried out using ‘Expand Long Template Enzyme’ mix (roche Applied Science) with forward primer (5′ AATGCTGGGAAGCTCACCTACATA 3′) (SEQ ID NO: 23) and reverse primer (5′ D3-GCTTGTGTTCTGGGATGAAGATTTC 3′) (SEQ ID NO: 24), which was fluorescent labeled with D3 dye. The amplified product was then analyzed in the Beckman CEQ8000 using Fragment Analysis Program. 1 μl (5%) of PCR product was denatured in 39 μl of SLS buffer (Beckman) containing DNA standard size markers. Two DNA standard size markers, DNA size standard marker kit 600 (0.5 μl/reaction) (Beckman) and custom made D1 labeled 600-1200 size marker (1 μl/reaction) (Bioventures, Inc) were used in to cover the DNA size from 60 to 1200 nucleotides.
Transfection
T cells were plated at around 60-80% confluence 16 hours before transfection. 2 μg (1 well in 6 well plate) or 10 μg (10 cm plate) of DNA was diluted in 100 μl (1 well in 6 well plate) or 500 μl (10 cm plate) of Opti-MEM (Invitrogen). FuGENE HD (Roche) was added to the diluted DNA at concentration of 4 μl per 1 μg of DNA. The mixture was then incubated at room temperature for 15 minutes to allow the DNA complex formation. After incubation, the mixture was added to the culture medium. The transfected cells were then analyzed after 36-48 hours.
Purification of Δ9 Protein
Expression construct of Δ9 gene was transiently transfected into 293T cells by Fugene HD transfection reagent (Roche applied science). The culture medium from the transfected cells was collected and then concentrated using Amicon ultra centrifugal filter 30K (Millipore). C-terminal flag-tagged Δ9 protein was immuno-precipitated from the concentrated medium using anti-flag M2 affinity gel (Sigma) according to the manufacture's instructions. The precipitated Δ9 protein was eluted by excessive Flag peptide (Sigma). The quality and quantity of purified Δ9 were measured by PAGE gels (Bio-rad) stained with Coomassie Blue (Bio-rad).
Western Blotting Analysis
Cells were collected, washed in PBS and lysed in ProteoJET mammalian cell lysis reagent (Fermentas) with protease and phosphatase inhibitors (Sigma). Lysates were centrifuged and supernatants were prepared for SDS-PAGE by addition of sample loading buffer (Bio-Rad). Lysates were subjected to 4-12% PAGE (Bio-Rad) and transferred to Immun-Blot PVDF membrane (Bio-Rad) per manufacturer's recommendations. Membranes were blocked in 5% milk/TPBT at room temperature for 1 hour. Membranes were first probed with antibodies against p-STAT1, p-STAT2, p-STAT3 or p-STAT5 (cell signaling technology), and then stripped and reprobed for STAT1, STAT2, STAT3 or STAT5 (cell signaling technology).
Real-Time PCR
Naive T-cells were differentiated under TH-17 condition for 5 days. Differentiated cells were collected and RNA was extracted by Trizol (Invitrogen). RNA was reverse transcribed into cDNA by AffinityScript QPCR cDNA Synthesis Kit (Stratagene) according to the manufacture's instructions. The real-time PCR was performed using Brilliant II SYBR Green QPCR Master Mix (Stratagene). The following primers were used in the study:
In Vitro Binding Assay
Recombinant proteins, including IL-23 (200 ng, humanzyme), IL-12 (200 ng, humanzyme) or soluble IL-12Rβ1 (1 μg, R&D), were added to the concentrated culture media from 293T cell transfected with empty vector or Δ9 expression construct. Δ9 protein was immuno-precipitated by Anti-Flag M2 affinity gel (Sigma). Precipitated proteins were eluted by addition of excessive Flag-peptide (Sigma) and separated by SDS-PAGE (Bio-rad). Anti-IL-12/23 p40 (R&D) and Anti-His tag (Invitrogen) were used to detect IL-12/IL-23 and IL-12Rβ1 respectively in the immunoblot assay.
Glycosylation modification on Δ9 protein was removed by PNGase F treatment (NEB) according to the manufacture's instructions. Recombinant IL-23 (200 ng) was added to the treated and untreated Δ9 protein followed by immuno-precipitation using Anti-Flag M2 affinity gel (Sigma). Anti-IL-12/23 p40 was used in the immunoblot to detect recombinant IL-23.
Transfection of 293T Cells
One day before the transfection experiment, 293T cells were trypsinized and cultured on the 10-cm culture plate. The cell density was at around 80% confluency at the time of transfection. 10 μg of DNA was mixed with 500 μl of OptiMEM (Invitrogen). 40 μl of FuGene HD transfection reagent (Roche) was diluted in 500 μl of OptiMEM. The diluted transfection reagent was then added to DNA mix and vortex for two seconds to mix the contents. The mixture was incubated at room temperature for 15 minutes before addition to the 293T cells. Both culture media and cell lysates were prepared after 48 hours post-transfection for purification of Δ9 protein.
Purification of Intracellular Δ9 Protein
Cells were collected, washed in PBS and lysed in ProteoJET mammalian cell lysis reagent (Fermentas) with protease and phosphatase inhibitors (Sigma). Lysates were centrifuged and supernatants were prepared for purification. C-terminal flag-tagged Δ9 was immuno-precipitated from cellular lysates using anti-flag M2 affinity gel (Sigma) according to the manufacture's instructions. The precipitated Δ9 was eluted by excessive Flag peptide (Sigma). The quality and quantity of the purified Δ9 were measured by PAGE gels (Bio-Rad) and stained with Coomassie Blue (Bio-Rad).
Purification of Δ9 Protein from Culture Medium
The purification of Δ9 protein from culture medium was the same as that of the intracellular Δ9, except the concentrated cultured media were used. The culture medium from the transfected cells was first collected and then concentrated using Amicon ultra centrifugal filter 30K (Millipore). The purification steps of Δ9 include:
-
- (1) Transfecting Δ9 expression construct into 293T cells;
- (2) Collecting culture media after 48 hours, 72 hours or 96 hours post-transfection;
- (3) Centrifugating to remove dead cells and unattached cells;
- (4) Concentrating culture media using Amicon Ultra-15 Centrifugal Filter with 30 kDa cutoff;
- (5) Immuno-precipitating Δ9 by anti-Flag M2 Affinity Gel;
- (6) Eluting Δ9 by excessive Flag peptides; and
- (7) Measuring the quantity and purity of purified Δ9 by gel electrophoresis and Commassie Blue staining.
Immunoblot Assay (Western Blotting)
Cells were collected, washed in PBS and lysed in ProteoJET mammalian cell lysis reagent (Fermentas) with protease and phosphatase inhibitors (Sigma). Lysates were centrifuged and supernatants were prepared for SDS-PAGE by addition of sample loading buffer (Bio-Rad). Lysates were subjected to 4-12% PAGE (Bio-Rad) and transferred to Immun-Blot PVDF membrane (Bio-Rad) per manufacturer's recommendations. Membranes were blocked in 5% milk/TPBT at room temperature for 1 hour. Membranes were probed with anti-FLAG (sigma), mouse anti-human IL-23Rα (R&D) and biotinlyated goat anti-human IL-23Rα (R&D).
Expression and Detection of Δ9
Expression constructs for both wt HuIL23Rα and Δ9 spliced variant were prepared. cDNA of each form was subcloned into pcDNA3.3 TOPO vector, using the TA cloning kit from Invitrogen (Carlsbad Calif.). Both forms were tagged with the “FLAG” sequence at the C-terminus and 293T cells were transiently transfected. Cell lysates and culture media were harvested after 48 hours and immunoblotted using Anti-FLAG M2 antibody. To measure the level of soluble hIL-23Rα (Δ9), a sandwich ELISA was developed using mouse anti-hIL-23Rα and biotinlyated goat anti-hIL-23Rα, and calibrated with IL-23R/Fc fusion protein (R&D Systems). The ELISA was validated against conditioned media from two independent transfection experiments. Plasma samples from healthy human with no history of Crohn's disease were obtained either purchased from the Innovative Research (Michigan) or collected from volunteers. Plasma from ten (10) Crohn's patients was obtained from Asterand.
Biochemical Properties of Δ9 Protein
Culture medium from Δ9 transfection experiments was concentrated using Amicon ultra centrifugal filter 30K (Millipore), then Δ9 protein was affinity purified using anti-FLAG M2 affinity gel (Sigma). The immuno-complex was precipitated, washed and resuspended in PBS. 200 ng of either IL-12 or IL-23 was added to the suspension and incubated at 4° C. for 2 hours. Reprecipitated FLAG-tagged Δ9 immuno-complex was again precipitated and eluted with excess FLAG peptide. The eluted product was analysed by immunoblot using anti-human p40 or anti-human IL-23R to detect the common p40 subunit of IL-12/IL-23 or Δ9, respectively. In some cases, recombinant human His-tagged soluble IL-12Rβ1 (1 μg/reaction; R&D Systems) was spiked into the suspension containing Δ9 bound to anti-FLAG M2 affinity gel, in the presence or absence of 200 ng IL-23. After extensive washing, the eluted product was analysed using anti-HIS (Invitrogen, Carlsbad Calif.), anti-human p40 or anti-human IL-23R(R&D Systems) to detect soluble IL-12Rβ1, the p40 subunit of IL-23 or Δ9, respectively. To examine the N-glycosylation modification on soluble human IL-23Rα, purified Δ9 was treated with N-Glycosidase F (PNGase F) at 37° C. for 1 hour followed by immunoblotting using anti-human IL-23R. Recombinant IL-23 (200 ng) was added to Δ9 protein or PNGase F-treated Δ9 protein. Immuno-precipitation was performed and analysed by immunoblot, probing with anti-hIL-12/23p40.
Competitive ELISA
To determine if our recombinant proteins (Δ9, Δ8,9 and 1-250) could inhibit the binding of IL-23 to IL-23R, competitive ELISA was developed.
Recombinant human IL-23R—Fc (2 μg/ml) (from R&D) was coated onto plates as a capture reagent. Biotinylated anti-p40 antibody (1:250) (which specifically recognizes the p40 subunit of IL-23) was used as a detection antibody. Streptavidin-horseradish peroxidase (HRP) (1:500) was added to detect the biotinlyated anti-p40 antibody. The peroxidase activity (representing the level of IL-23 captured onto plates) was measured by addition of a tetramethylbenzidine (TMB) substrate (100 μl/well). The color intensity was directly proportion to the amount of the bound IL-23 protein. The color was measured at optical density (OD) 450 nm using a microtiter plate reader.
Δ9 and IL-23 Signaling in Human PBMC
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinised whole venous blood of healthy donors by density gradient centrifugation using Ficoll-Paque (Sigma-Aldrich, St Louis, Mo., USA). Blood was purchased as anonymous buffy coats from New Jersey blood transfusion service. Isolated PBMCs were rested in RPMI-1640 medium (Invitrogen-Gibco, Carlsbad, Calif.) supplemented with 10% heat-inacticated foetal bovine serum (Invitrogen-Gibco) and 1 mM glutamine (Invitrogen-Gibco) at 37° C. for 24 hours. PBMCs were then stimulated with 10 ng/mL IL-23 for 20 mins. Cell lysates were prepared for immunoblots to examine the phorphorylation status of STATs. Membranes were probed with antibodies against p-STAT1, p-STAT2, p-STAT3 or p-STAT5 (Cell Signaling Technology), then stripped and reprobed for total STAT1, STAT2, STAT3 or STAT5 (Cell Signaling Technology). In some cases PBMC were stimulated in the presence of supernatant containing human IL23RαΔ9 protein, titrated as shown.
Purification of Δ9 Protein
T cell supernatant containing FLAG-tagged HuIL23RαΔ9 protein was collected and concentrated using Amicon ultra centrifugal filter 30K (Millipore), then precipitated using anti-FLAG M2 affinity gel (Sigma). Precipitated Δ9 was eluted with excess FLAG peptide (Sigma). 10 μl of purified Δ9 was used in the PAGE gels (Bio-Rad), followed by Coomassie Blue (Bio-Rad) staining.
Differentiation of Human Th17 Cells.
Naive CD4′ human T-cells were obtained by negative enrichment (StemCell Technologies, Vancouver). Their purity was assessed by Flow cytometry. Of the 96% CD4′ T-cells prepared, 98% were CD45RA+, CD45R0−. CD4+ naive T-cells were cultured for 5 days under the influence of anti-CD3+ anti-CD28 and a “Th-17 differentiation” cytokine cocktail (10 ng/mL of IL-1, 10 ng/mL of IL-6 and 1 ng/mL of TGF-β) in the presence of 5 ng/mL of IL-23, 500 ng/mL of Δ9 or IL-23/Δ9 complex. Th17 differentiation was assessed by measuring the mRNA transcript levels of four crucial transcription factors (T-bet, GATA-3, Foxp3 and RORγt). In some cases as shown, IL-17A and IL-17F were quantitated by ELISA (R&D Systems).
ELISA
Sandwich ELISA was developed using 5 μg/ml of mouse anti-human IL-23R (R&D) as capture antibody and 1.6 μg/ml of Goat biotinlyated anti-human IL-23R(R&D) as detection antibody. Capture antibody was first coated on the microtiter plate using 50 mM of bicarbonate buffer (pH=9.6) at 4° C. overnight. The plate was then blocked with 10% FBS/TBST at room temperature for 2 hours. Samples were added to the well and incubated at 4° C. overnight. Detection antibody in TBST was added to the wells and incubated at room temperature for 2 hours. The plate was extensively washed with TBST during each change. The immuno-complex was detected by addition of Streptavidin-HRP (R&D) and TMB substrate (eBioscience). The plate was read at OD450nm.
While the present invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations of the invention thereof. One of skill in the art will recognize that various modifications may be made to the embodiments described herein without departing from the spirit and scope of the invention, which is defined by the appended claims. All the references and patents cited in this application are incorporated by reference in their entirety.
REFERENCES
- 1. Langrish C L, Chen Y, Blumenschein W M et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201:233-240.
- 2. Harrington L E, Hatton R D, Mangan P R et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005; 6:1123-1132.
- 3. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13:715-725.
- 4. Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbetal and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002; 168:5699-5708.
- 5. Aggarwal S, Ghilardi N, Xie M H, de Sauvage F J, Gurney A L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol. Chem. 2003; 278:1910-1914.
- 6. Yang X O, Panopoulos A D, Nurieva R et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol. Chem. 2007; 282:9358-9363.
- 7. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007; 19:362-371.
- 8. Ouyang W, Kolls J K, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008; 28:454-467.
- 9. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009; 123:1004-1011.
- 10. Mangan P R, Harrington L E, O'Quinn D B et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006; 441:231-234.
- 11. Veldhoen M, Hocking R J, Atkins C J, Locksley R M, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24:179-189.
- 12. Wei L, Laurence A, Elias K M, O'Shea J J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol. Chem. 2007; 282:34605-34610.
- 13. Zhou L, Ivanov I I, Spolski R et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007; 8:967-974.
- 14. Ivanov I I, McKenzie B S, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126:1121-1133.
- 15. Yang X O, Pappu B P, Nurieva R et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008; 28:29-39.
- 16. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15:1090-1100.
- 17. Wakashin H, Hirose K, Iwamoto I, Nakajima H. Role of IL-23-Th17 cell axis in allergic airway inflammation. Int Arch Allergy Immunol. 2009; 149 Suppl 1:108-112.
- 18. Chan J R, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203:2577-2587.
- 19. Murphy C A, Langrish C L, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003; 198:1951-1957.
- 20. Wong C K, Lit L C, Tam L S, Li E K, Wong P T, Lam C W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127:385-393.
- 21. Cardoso C R, Garlet G P, Crippa G E et al. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol. 2009; 24:1-6.
- 22. Elson C O, Cong Y, Weaver C T et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007; 132:2359-2370.
- 23. Duerr R H, Taylor K D, Brant S R et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314:1461-1463.
- 24. Cargill M, Schrodi S J, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007; 80:273-290.
- 25. Farago B, Magyari L, Safrany E et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis. 2008; 67:248-250.
- 26. Kan S H, Mancini G, Gallagher G. Identification and characterization of multiple splice forms of the human interleukin-23 receptor alpha chain in mitogen-activated leukocytes. Genes Immun. 2008; 9:631-639.
- 27. Mancini G, Kan S H, Gallagher G. A novel insertion variant of the human IL-23 receptor-alpha chain transcript. Genes Immun. 2008; 9:566-569.
- 28. Presky D H, Yang H, Minetti L J et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA. 1996; 93:14002-14007.
- 29. Cua D J, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003; 421:744-748.
- 30. Murphy K M, Reiner S L. The lineage decisions of helper T cells. Nat Rev Immunol. 2002; 2:933-944.
- 31. Liang S C, Tan X Y, Luxenberg D P et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006; 203:2271-2279.
- 32. Harrington L E, Mangan P R, Weaver C T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol. 2006; 18:349-356.
- 33. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52:65-70.
- 34. Zheng Y, Danilenko D M, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007; 445:648-651.
Claims
1. A method of inhibiting IL-23R-mediated cell signaling in a mammalian cell, comprising the steps of:
- a) providing a mammalian cell in need thereof;
- b) providing a recombinant IL-23Rα protein, said recombinant IL-23Rα protein has an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4; and
- c) exposing said mammalian cell to an effective amount of said recombinant IL-23Rα protein, thereby inhibits IL-23R mediated cell signaling in said mammalian cell.
2. The method of claim 1, wherein said recombinant IL-23Rα protein has an amino acid sequence consisting of SEQ ID NO: 2.
3. The method of claim 1, wherein said recombinant IL-23Rα protein has an amino acid sequence consisting of SEQ ID NO: 4.
4. The method of claim 1, wherein said IL-23 mediated cell signaling is phosphorylation of STAT1, STAT2, STAT3, or STAT5.
5. The method of claim 1, wherein said IL-23 mediated cell signaling is phosphorylation of STAT3.
6. The method of claim 1, wherein said IL-23 mediated cell signaling is secretion of IL-17A or IL-17F.
7. The method of claim 1, wherein said IL-23 mediated cell signaling is secretion of IL-17A.
8. The method of claim 1, wherein said IL-23 mediated cell signaling is Th-17 cell maturation.
9. The method of claim 1, wherein said mammalian cell is a human cell.
10. The method of claim 1, wherein said mammalian cell is 293T cell.
Type: Application
Filed: Jan 23, 2013
Publication Date: Jul 18, 2013
Inventors: Grant Gallagher (Milltown, NJ), Raymond Yu (East Brunswick, NJ), Jonathan Brazaitis (Parlin, NJ)
Application Number: 13/748,066
International Classification: C12N 5/071 (20060101);
